tirzepatide compounding ruling Lilly asks to join lawsuit over compounded versions of its weight-loss drugs changer for advanced Compounded Tirzepatide

All prescriptions require an online medical evaluation with an independent licensed healthcare provider

Tirzepatide is a GIP/GLP-1 dual-receptor agonist administered as a weekly subcutaneous injection

[DOI] [PMC free article] [PubMed] [Google Scholar] 25.Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Choose the next site in your rotation cycle

Recommended subcutaneous sites include the abdomen, upper thighs, or the back of the upper arms

After six months on Mounjaro, I hit my goal weight of 140 pounds